Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015.
Company completes four Focal One sales, including three bundled sales that combine Focal One® with Exact Imaging’s ExactVu micro ultrasound imaging solution Company recorded an additional three stand-alone ExactVu purchase orders at major centers LYON, France , July 15, 2020 -- EDAP TMS SA (Nasdaq:
Appointment adds significant medical technology executive and board leadership experience LYON, France , June 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announced today that veteran medical technology executive Marie Meynadier has
Seasoned medical technology sales and marketing professional brings more than 25 years of experience to the EDAP team Joins EDAP from Exact Imaging to lead the recently announced global distribution agreement between the two companies LYON, France , May 28, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the
Maintains strong balance sheet with EUR 18.5 million ( USD 20.3 million ) in cash as of March 31, 2020 Signs exclusive worldwide distribution agreement with Exact Imaging to combine their innovative micro-ultrasound technology with Focal One to offer an end-to-end focal therapy solution for the
Exact Imaging is a leading developer of ultra-high-resolution micro-ultrasound diagnostic technologies Micro-ultrasound ExactVu™ is the only ultrasound-based imaging tool with published data demonstrating prostate cancer diagnostic capabilities similar to MRI Combination of Exact Imaging’s
Company to host conference call and webcast on Thursday, May 14 at 8:30 am EDT LYON, France , May 6, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2020 after the
Record full year 2019 revenues of €44.9 million, representing 14.6% year-over-year growth HIFU full year 2019 revenue growth of 28% driven by 54% growth in US installed base Record 46.8% gross profit margin driven by HIFU growth Profitable for the full year 2019 with operating income of €2.2
Company to host conference call and webcast on Tuesday, March 31 st @ 8:30 am EDT LYON, France , March 24, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended
LYON, France , March 17, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders: To my fellow shareholders, The COVID-19 virus represents a new challenge for us all, and I want to formally update
